Today, according to reports, Debut, a synthetic biology company that previously received $40 million in Series B funding from L’Oréal’s venture capital fund BOLD, has launched its first skincare brand called Deinde.
It is reported that Deinde has introduced three products: a facial cleanser, a face mask, and a serum. Deinde’s formulations contain ceramides, recyclable date palm seed extract, and bio-inspired tripeptides, aiming to address and prevent skin inflammation. Of particular note, the main ingredients in the latter two products are the brand’s developed biotechnological anti-inflammatory ingredient called “naringenin.”
Dominque Gagnon, Vice President of Consumer Brands at Debut, said, “We are capitalizing on the new wave of preventive care, addressing the concerns of consumers in their twenties and thirties to maintain skin health rather than repairing skin damage that has already occurred. Improving productivity by streamlining business processes is also our top priority.” Additionally, he added that Debut conducts ingredient screening, testing, and formulation internally, stating, “This allows us to commercialize very quickly, which is crucial for a company that has proven its relevance and profitability.”
Although specific sales expectations after the launch were not disclosed, industry experts believe that Deinde’s first-year sales could reach $3 million to $5 million.
